Clinical trial results of the LensAR Laser System to be presented at the 2009 AAO and PAAO joint meeting

NewsGuard 100/100 Score

LensAR, Inc., a leading developer of next generation laser technology for cataract surgery and other ocular applications, today announced that data from a recently completed clinical trial of the LensAR Laser System will be presented at the upcoming 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and Pan-American Academy of Ophthalmology (PAAO). The meeting will be held October 23 - 27, 2009 in San Francisco, CA.

Clinical investigator Louis D. "Skip" Nichamin, M.D., medical director of the Laurel Eye Clinic Center in Brookville, PA, will present LensAR's clinical results in a paper entitled, "Laser Capsulotomy with the LensAR Laser System," on Friday, October 23, 2009. The paper will be presented during Section II: Cataract and Refractive Surgery, "Refractive Surgery 2009: It's Time to Change," at 9:08 a.m. Pacific in Moscone Center West, Room 2014.

In addition to the data presentation, Ramon Naranjo-Tackman, M.D., principal investigator for LensAR's clinical studies in Mexico, professor of ophthalmology at the Universidad Nacional Autonoma de Mexico, and director of corneal service at the Asociacion Para Evitar la Ceguera en Mexico, Hospital Luis Sanchez Bulnes in Mexico City will give a guest talk entitled, "Novel Uses of a Femtosecond Laser." Dr. Naranjo will present an overview of the early experiences with capsulotomy and nuclear fragmentation with the LensAR Laser System. His talk will take place during Section XII: Pan-American Association of Ophthalmology (PAAO) Symposium, scheduled for Saturday, October 24, 2009 at 1:30 p.m. Pacific in Moscone Center West, Room 2014.

Source:

LensAR, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New model predicts kidney injury risk in cancer patients on cisplatin